Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Journal of Clinical Nutrition

• Publication date

  2010-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3945/ajcn.2009.28422PMID 20181806
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results.

  2008cited by this paper
• Atorvastatin and Fenofibrate Have Comparable Effects on VLDL–Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome

  2008cited by this paper
• Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

  2008cited by this paper
• Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.

  2008cited by this paper
• Dose-Dependent Effect of Rosuvastatin on VLDL–Apolipoprotein C-III Kinetics in the Metabolic Syndrome

  2008cited by this paper
• Effect of weight loss on markers of triglyceride‐rich lipoprotein metabolism in the metabolic syndrome

  2008cited by this paper
• n-3 fatty acids and human lipoprotein metabolism: An update

  2007cited by this paper
• Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma Published, JLR Papers in Press, March 23, 2006.

  2006cited by this paper
• Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.

  2006cited by this paper
• Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

  2005cited by this paper
• Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

  2004cited by this paper
• Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.

  2004cited by this paper
• Effect of sex and obesity on basal VLDL-triacylglycerol kinetics.

  2003cited by this paper
• Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.

  2003cited by this paper
• Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.

  2002cited by this paper
• New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism

  2002cited by this paper
• Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

  2002cited by this paper
• Peroxisome Proliferator-activated Receptor α Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil*

  2001cited by this paper
• VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial

  2000cited by this paper
• Insulin resistance and cardiovascular disease.

  2000cited by this paper
• Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.

  2000cited by this paper
• Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis.

  1999cited by this paper
• 3‐Hydroxy‐3‐methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C‐III and lipoprotein lipase

  1999cited by this paper
• Apolipoprotein B metabolism in hypertriglyceridemic diabetic patients administered either a fish oil- or vegetable oil-enriched diet.

  1998cited by this paper
• Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.

  1998cited by this paper
• Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity

  1998cited by this paper
• Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ

  1997cited by this paper
• Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.

  1997cited by this paper
• Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.

  1991cited by this paper
• Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration.

  1989cited by this paper
• Metabolism of apolipoprotein C-III in normolipemic human subjects.

  1988cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins.

  1985cited by this paper
• Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects.

  1981cited by this paper
• Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.

  1972cited by this paper

• Effects of fish oil intervention on type 2 diabetes early risk novel biomarkers in healthy middle-aged and elderly adults: a double-blind randomized controlled trial.

  2025cites this paper
• Synthesis of Enantiostructured Triacylglycerol Prodrugs Constituting an Active Drug Located at Terminal sn-1 and sn-3 Positions of the Glycerol Backbone

  2025cites this paper
• Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia

  2022cites this paper
• Unravelling Lipoprotein Metabolism with Stable Isotopes: Tracing the Flow.

  2021cites this paper
• The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: a meta-regression of randomized clinical trials.

  2021cites this paper
• Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism

  2019cites this paper
• Correcting VLDL Kinetic Abnormalities in Obesity and Insulin-Resistance

  2018cites this paper
• Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

  2018cites this paper
• Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials.

  2018cites this paper
• Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta‐analysis of randomised placebo‐control human clinical trials

  2018cites this paper
• Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials

  2018cites this paper
• The Effect of Docosahexaenoic Acid on Serum Levels of Apolipoproteins in Patients with Type-2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

  2018cites this paper
• Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol

  2017cites this paper
• Marine n-3 polyunsaturated fatty acids in renal transplantation

  2016cites this paper
• Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner

  2016cites this paper
• Targeting ApoC-III to Reduce Coronary Disease Risk

  2016cites this paper
• Role of Omega-3 Fatty Acids in Metabolic Syndrome

  2016cites this paper
• Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study

  2015cites this paper
• Synthesis of reversed structured triacylglycerols possessing EPA and DHA at their terminal positions

  2015cites this paper
• Does Fish Oil Have an Anti-Obesity Effect in Overweight/Obese Adults? A Meta-Analysis of Randomized Controlled Trials

  2015cites this paper
• Lipid-lowering efficacy of atorvastatin.

  2015cites this paper
• Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.

  2014cites this paper
• Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men

  2013cites this paper
• Lipid modifiers and NASH: statins, ezetimibe, fibrates and other agents

  2013cites this paper
• Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?

  2013cites this paper
• Activation of n-3 polyunsaturated fatty acids as oxime esters: a novel approach for their exclusive incorporation into the primary alcoholic positions of the glycerol moiety by lipase.

  2012cites this paper
• Lipid lowering efficacy of atorvastatin.

  2012cites this paper
• High-fat diets rich in soy or fish oil distinctly alter hypothalamic insulin signaling in rats.

  2012cites this paper
• Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update

  2011cites this paper
• Apolipoprotein CIII: 42 years old and even more interesting.

  2011cites this paper
• Role of ω3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors.

  2011cites this paper
• Nutrition and metabolism: nutritional therapy for disordered triglyceride metabolism and nonalcoholic fatty liver disease.

  2010cites this paper